Tretinoin

Generic Name: Tretinoin

Brand Names: Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈O_₂

CAS Number: 302-79-4

Unique Ingredient Identifier: 5688UTC01R

Background: Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...

Indication: Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...

Associated Conditions: Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin

Associated Therapies: -

Clinical Trials

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: mercaptopurine
Drug: methotrexate
Drug: tretinoin

First Posted Date: 2007-06-27

Last Posted Date: 2023-01-10

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 105

Registration Number: NCT00492856

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸
Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States

and more 206 locations

Phase III Trial in Acute Promyelocytic Leukemia Patients

Phase 3

Completed

Conditions: Leukemia

Interventions: Drug: arsenic trioxide
Drug: idarubicin
Drug: all-trans retinoic acid (ATRA)
Drug: mercaptopurine
Drug: methotrexate
Drug: all-trans retinoic acid

First Posted Date: 2007-06-05

Last Posted Date: 2022-10-12

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 276

Registration Number: NCT00482833

Locations: 🇦🇹
Universitätsklinik Innsbruck Hämatologie Onkologie, Innsbruck, Austria
🇦🇹
Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria
🇦🇹
Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria

and more 106 locations

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

First Posted Date: 2007-02-26

Last Posted Date: 2018-08-07

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 62

Registration Number: NCT00439673

Locations: 🇮🇹
Ospedale Reg. A di Summa, Brindisi, Italy
🇮🇹
Ospedale A. Businco, Cagliari, Italy
🇮🇹
Università degli studi di Roma La Cattolica, Roma, Italy

and more 4 locations

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Phase 4

Completed

Conditions: Acute Promyelocytic Leukemia

First Posted Date: 2006-12-06

Last Posted Date: 2014-10-28

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 300

Registration Number: NCT00408278

Locations: 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸
Hospital de Cruces, Santander, Spain
🇪🇸
Hospital de Santiago de Compostela, Santiago de Compostela, Spain

and more 37 locations

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: decitabine
Drug: tretinoin
Genetic: DNA methylation analysis
Genetic: cytogenetic analysis
Genetic: microarray analysis
Other: flow cytometry
Other: immunohistochemistry staining method

First Posted Date: 2006-09-28

Last Posted Date: 2024-05-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT00382200

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2006-01-13

Last Posted Date: 2014-04-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00276601

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 4 locations

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: All-trans retinoic acid
Drug: Pegfilgrastim

First Posted Date: 2005-09-08

Last Posted Date: 2017-09-20

Lead Sponsor: University of Ulm

Target Recruit Count: 920

Registration Number: NCT00151242

Locations: 🇩🇪
Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany
🇦🇹
Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria
🇩🇪
Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 31 locations

All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-08

Last Posted Date: 2017-04-19

Lead Sponsor: University of Ulm

Target Recruit Count: 500

Registration Number: NCT00151255

Locations: 🇦🇹
Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇩🇪
Medical Department I, Hospital of Bremen-Mitte, Bremen, Germany
🇩🇪
Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 26 locations

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

First Posted Date: 2005-08-29

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00136461

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: IL-2
Drug: ATRA

First Posted Date: 2005-01-07

Last Posted Date: 2013-08-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT00100906

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy